• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[肺部:多种疾病的起始点]

[The lungs: starting point for many diseases].

作者信息

Hasseli Rebecca, Gall Henning, Richter Manuel J

机构信息

Medizinische Klinik II, Universitätsklinikum Gießen und Marburg GmbH, Standort Gießen, Mitglied des Deutschen Zentrums für Lungenforschung (DZL), Klinikstr. 32, 35392, Gießen, Deutschland.

出版信息

Inn Med (Heidelb). 2023 Apr;64(4):329-339. doi: 10.1007/s00108-022-01443-4. Epub 2022 Dec 23.

DOI:10.1007/s00108-022-01443-4
PMID:36562845
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9786524/
Abstract

The lungs are a frequent site for the manifestation of systemic, neoplastic and immunological multiorgan diseases. In the clinical routine, patients frequently present with symptoms from the respiratory spectrum of disorders, such as dyspnea. After a clinical examination, lung function testing and imaging an initial pulmonary manifestation can often be detected; however, the ultimate assignment to a systemic disease is usually only successful in the synopsis of the clinical results, pulmonary involvement, extrapulmonary manifestation and further diagnostics. This review article presents three systemic diseases that become clinically relevant due to the primary pulmonary manifestations.

摘要

肺是全身性、肿瘤性和免疫性多器官疾病常见的表现部位。在临床实践中,患者常出现呼吸系统疾病谱中的症状,如呼吸困难。经过临床检查、肺功能测试和影像学检查后,通常能够检测到最初的肺部表现;然而,要最终确诊为全身性疾病,通常只有在综合临床结果、肺部受累情况、肺外表现及进一步诊断后才能成功。这篇综述文章介绍了三种因原发性肺部表现而具有临床相关性的全身性疾病。

相似文献

1
[The lungs: starting point for many diseases].[肺部:多种疾病的起始点]
Inn Med (Heidelb). 2023 Apr;64(4):329-339. doi: 10.1007/s00108-022-01443-4. Epub 2022 Dec 23.
2
Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes.结节病性肺纤维化。临床特征和结局。
Ann Am Thorac Soc. 2013 Aug;10(4):362-70. doi: 10.1513/AnnalsATS.201303-069FR.
3
[Pulmonary hypertension in chronic respiratory diseases].[慢性呼吸道疾病中的肺动脉高压]
Presse Med. 2014 Sep;43(9):945-56. doi: 10.1016/j.lpm.2014.07.006. Epub 2014 Aug 11.
4
Lung transplantation in patients with scleroderma.硬皮病患者的肺移植。
Curr Opin Rheumatol. 2013 Nov;25(6):714-8. doi: 10.1097/01.bor.0000434670.39773.a8.
5
[Sarcoidosis as prime example of a granulomatous disease].[结节病作为肉芽肿性疾病的典型例子]
Z Rheumatol. 2022 Sep;81(7):535-548. doi: 10.1007/s00393-022-01245-x. Epub 2022 Aug 4.
6
The Clinical Features of Sarcoidosis: A Comprehensive Review.结节病的临床特征:全面综述。
Clin Rev Allergy Immunol. 2015 Aug;49(1):63-78. doi: 10.1007/s12016-014-8450-y.
7
[Pneumothorax secondary to pulmonary histiocytosis X].[继发于肺组织细胞增多症X的气胸]
Minerva Chir. 1999 Jul-Aug;54(7-8):531-6.
8
Lung transplantation for cystic lung diseases: lymphangioleiomyomatosis, histiocytosis x, and sarcoidosis.囊性肺疾病的肺移植:淋巴管平滑肌瘤病、肺嗜酸性肉芽肿和结节病。
Semin Respir Crit Care Med. 2001 Oct;22(5):509-16. doi: 10.1055/s-2001-18423.
9
Severe pulmonary hypertension in histiocytosis X.组织细胞增多症X中的重度肺动脉高压。
Am J Respir Crit Care Med. 2000 Jan;161(1):216-23. doi: 10.1164/ajrccm.161.1.9807024.
10
Management of interstitial lung disease associated with connective tissue disease.与结缔组织病相关的间质性肺疾病的管理
BMJ. 2016 Feb 24;352:h6819. doi: 10.1136/bmj.h6819.

本文引用的文献

1
Prevalence of aortic stenosis and TAVR outcomes in patients with systemic sclerosis-associated pulmonary hypertension.系统性硬化症相关肺动脉高压患者主动脉瓣狭窄的患病率及经导管主动脉瓣置换术的结局
Pulm Circ. 2022 Jul 1;12(3):e12118. doi: 10.1002/pul2.12118. eCollection 2022 Jul.
2
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.2022年欧洲心脏病学会/欧洲呼吸学会肺动脉高压诊断和治疗指南。
Eur Respir J. 2023 Jan 6;61(1). doi: 10.1183/13993003.00879-2022. Print 2023 Jan.
3
Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative-Group 3 pulmonary hypertension.
间质性肺疾病中肺动脉高压的临床意义:肺血管研究所创新药物开发倡议 - 3型肺动脉高压共识声明
Pulm Circ. 2022 Jul 1;12(3):e12127. doi: 10.1002/pul2.12127. eCollection 2022 Jul.
4
Respiratory system as the main determinant of dyspnea in patients with pulmonary hypertension.呼吸系统是肺动脉高压患者呼吸困难的主要决定因素。
Pulm Circ. 2022 Mar 23;12(1):e12060. doi: 10.1002/pul2.12060. eCollection 2022 Jan.
5
[Nailfold capillaroscopy-Principles and clinical application].[甲襞毛细血管镜检查——原理与临床应用]
Z Rheumatol. 2022 May;81(4):313-322. doi: 10.1007/s00393-022-01200-w. Epub 2022 Apr 21.
6
[Modern drug therapy for systemic sclerosis associated interstitial lung disease].[系统性硬化症相关间质性肺疾病的现代药物治疗]
Dtsch Med Wochenschr. 2022 Feb;147(4):179-186. doi: 10.1055/a-1658-5176. Epub 2021 Dec 3.
7
Langerhans cell histiocytosis with lung involvement in isolation and multisystem disease: Staging, natural history, and comparative survival.孤立性肺受累与多系统疾病的朗格汉斯细胞组织细胞增生症:分期、自然病程和比较生存。
Am J Hematol. 2021 Dec 1;96(12):1604-1610. doi: 10.1002/ajh.26355. Epub 2021 Oct 8.
8
Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial.尼达尼布治疗进行性肺间质疾病:来自 INBUILD 试验的全部数据。
Eur Respir J. 2022 Mar 17;59(3). doi: 10.1183/13993003.04538-2020. Print 2022 Mar.
9
[Prevention by vaccination of adult patients with pulmonary diseases].通过接种疫苗预防成年肺部疾病患者
Pneumologe (Berl). 2021;18(5):327-338. doi: 10.1007/s10405-021-00402-4. Epub 2021 Jul 12.
10
ERS clinical practice guidelines on treatment of sarcoidosis.ERS 临床实践指南:结节病的治疗。
Eur Respir J. 2021 Dec 16;58(6). doi: 10.1183/13993003.04079-2020. Print 2021 Dec.